For compounding pharmacies preparing sterile medications, the margin for error is essentially zero. A single microbial contaminant in an injectable preparation, an ophthalmic solution, or an intrathecal drug can cause severe infection, sepsis, or death. This is precisely why USP General Chapter <71> Sterility Tests stands as the foundational quality standard for verifying that compounded sterile preparations (CSPs) are free of viable microorganisms.

With sweeping updates to USP <797> now officially in effect since November 1, 2023, the relationship between <71> and sterile compounding has never been more consequential — or more scrutinized. This post unpacks what <71> requires, why each element matters, and how key testing materials like Soybean Casein Digest Medium (SCDM -see BD 211768), Fluid Thioglycollate Medium (FTM), and capsule membrane filters (see Whatman Cytiva Capsule Filters) are central to a credible sterility program.

What is USP <71> and why does it matter?

USP <71> Sterility Tests is the United States Pharmacopeia's compendial framework for detecting the presence of viable microorganisms in products labeled as "sterile." It has been harmonized with the European Pharmacopoeia (EP <2.6.1>) and the Japanese Pharmacopoeia (JP <4.06>), making it a globally recognized benchmark for pharmaceutical safety.

For compounding pharmacies, the standard operates in direct partnership with USP <797>, which defines conditions for preparing compounded sterile preparations. Under the updated <797> framework, Category 3 CSPs — those assigned the longest beyond-use dates (BUDs) — must pass <71> sterility testing as a condition of release. Importantly, the standard itself acknowledges a fundamental limitation: sterility testing cannot confirm absolute sterility in a batch, because only a statistical sample is tested. Its real power lies in detecting gross contamination and in validating that aseptic processes are under control.

This distinction is critical: sterility testing is a verification layer — not a replacement for sound aseptic technique, environmental controls, and robust quality systems.

The two methods of USP <71> testing

USP <71> specifies two procedural approaches. The choice between them depends on the nature of the product being tested.

Membrane filtration

Membrane filtration is the preferred method for most filterable pharmaceutical products, including aqueous, alcoholic, and oily solutions, as well as preparations that can be dissolved or emulsified. The product is passed through a sterile membrane with a nominal pore size of ≤0.45 µm, which physically retains any microorganisms present. The membrane is then aseptically transferred into culture media and incubated for a minimum of 14 days. This method is particularly valued because it removes antimicrobial substances from the product before incubation, reducing the risk of false-negative results due to bacteriostasis or fungistasis.

Direct inoculation

Direct inoculation (also called direct transfer) is employed when the product cannot be filtered — for example, ointments, creams, suspensions, or bulk solids. A specified quantity of the product is transferred aseptically into both culture media. Because the product's antimicrobial properties are not removed, this method carries a higher risk of interfering with microbial growth; it should be reserved for situations where filtration is genuinely not feasible.

Critical materials in USP <71> sterility testing

Reliable sterility testing depends not only on proper technique but on selecting the right materials for culture, filtration, and recovery. The three materials below are central to any compliant testing program.

SCDM: the universal aerobic and fungal detector

Soybean Casein Digest Medium — also known as Tryptic Soy Broth (TSB) — is one of two media mandated by USP <71>. Its rich formulation, derived from pancreatic digest of casein and papaic digest of soybean meal, supports the growth of a wide spectrum of aerobic bacteria as well as fungi, including Aspergillus brasiliensis, Bacillus subtilis, and Candida albicans — all reference organisms specified in the USP <71> growth promotion test. SCDM is incubated at 20–25°C, a temperature range that favors fungal germination and the recovery of environmental aerobic contaminants. Any turbidity observed during the 14-day observation window must be investigated and adjudicated as either a true positive or a lab contamination event requiring invalidation and retesting.

FTM: reaching where aerobic broths can't

Fluid Thioglycollate Medium is the second required culture medium. Its defining feature is the inclusion of sodium thioglycollate, a reducing agent that depletes dissolved oxygen and creates a gradient within the container — aerobic at the top, anaerobic at the bottom. This architecture allows FTM to detect both aerobic bacteria (such as Staphylococcus aureus and Pseudomonas aeruginosa) and obligate anaerobes (notably Clostridium sporogenes). FTM is incubated at 30–35°C. A resazurin indicator dye provides a visual cue: the medium should remain pink only in the top portion; if more than the upper half has changed color, indicating excessive oxygen uptake, the medium should not be used. For anaerobic detection, shaking or agitation of FTM must be kept to a minimum to preserve the oxygen gradient.

Capsule membrane filters: asepsis by design

In the membrane filtration method, the choice of filtration hardware significantly affects the risk of false-positive results due to environmental contamination. Capsule membrane filters (also called closed-system filter units or filtration canisters) house the 0.45 µm membrane within a sealed, pre-sterilized housing. Unlike open filter holders, capsule designs minimize the number of aseptic manipulations, reduce analyst exposure to the product, and allow the culture medium to be added directly through the capsule without removing the membrane — dramatically lowering the risk of adventitious contamination. These units are particularly well-suited for ISO 5 biological safety cabinets where space is limited and every manipulation carries microbial risk. Method suitability testing must confirm that the specific capsule filter used does not retain or destroy microorganisms at levels that would compromise test sensitivity.

Method suitability: the testing step that validates the test itself

One of the most important — and frequently underappreciated — requirements of USP <71> is method suitability testing. Because many CSPs contain antimicrobial agents (antibiotics, preservatives), these substances can suppress microbial growth in culture media, generating falsely negative results. Method suitability must be performed whenever a new product is introduced or when formulation changes are made, such as an increase in active ingredient concentration or a change in antimicrobial class. The test confirms that the chosen method — whether membrane filtration or direct inoculation — adequately eliminates antimicrobial interference and allows the six reference organisms to achieve visible growth within the prescribed time frames.

This requirement places an important obligation on pharmacists: any formulation change must be communicated promptly to the testing laboratory so that method suitability can be re-evaluated before further sterility testing proceeds.

Incubation, observation, and interpreting results

Regulatory and compliance context

For 503A compounding pharmacies, USP <71> testing is required for Category 3 CSPs and is strongly recommended as a quality verification tool for high-risk preparations. For 503B outsourcing facilities, compliance with USP <71> in conjunction with FDA's cGMP standards (21 CFR Part 211) is mandatory for all sterile products. Many 503B facilities outsource sterility testing to FDA-registered, ISO 17025-accredited third-party laboratories that maintain validated test methods and controlled cleanroom environments.

State boards of pharmacy increasingly reference USP <797> and <71> in their inspection frameworks. Failure to perform required sterility testing — or to maintain records demonstrating compliance — is among the most common enforcement findings in sterile compounding inspections.

Beyond testing: sterility is built, not tested in

A passing USP <71> result provides meaningful assurance, but it is not the primary guarantor of product sterility. The statistical reality of batch sampling means that a contaminated batch can produce a passing test result if the contaminated units fall outside the sample. For this reason, USP <797> places its greatest emphasis on upstream controls: rigorous aseptic technique training, gloved fingertip and media fill testing, environmental monitoring programs, and facility design. USP <71> sterility testing is the final critical checkpoint — but the real work of sterility assurance happens in the cleanroom, long before the test tubes are filled.

Key takeaways for compounding pharmacists

USP <71> is not merely a regulatory checkbox — it is a scientific process with real consequences for patient safety. Ensuring your facility uses validated culture media (SCDM and FTM from qualified suppliers), appropriate closed-system capsule membrane filters, and a properly qualified testing laboratory with method suitability documentation is essential. Changes to formulations must trigger re-validation of test methods. And results — whether passing or failing — must be documented and acted upon in compliance with USP <797> and applicable state regulations.

Keywords: USP 71 sterility testing, compounding pharmacy sterility, SCDM sterility media, fluid thioglycollate medium FTM, capsule membrane filter sterility, USP 797 compliance, compounded sterile preparations, CSP sterility testing, membrane filtration pharmaceutical, aseptic compounding quality control